MX2021009743A - Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes. - Google Patents
Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes.Info
- Publication number
- MX2021009743A MX2021009743A MX2021009743A MX2021009743A MX2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- sub
- pkm2
- thieno
- pyrrole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente descripción se describen compuestos que regulan la actividad de la piruvato quinasa, composiciones farmacéuticas y métodos de uso de estos. Estos compuestos están representados por la Fórmula (I)(VER FORMULA) (I) en donde R2, L1-L2, U1-U7, m, anillo A, y Q son como se definen en la presentedescripción.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962805040P | 2019-02-13 | 2019-02-13 | |
PCT/US2020/017965 WO2020167976A1 (en) | 2019-02-13 | 2020-02-12 | Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021009743A true MX2021009743A (es) | 2021-11-12 |
Family
ID=69941460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021009743A MX2021009743A (es) | 2019-02-13 | 2020-02-12 | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220127267A1 (es) |
EP (1) | EP3924056A1 (es) |
JP (1) | JP2022520090A (es) |
KR (1) | KR20210128435A (es) |
CN (1) | CN113646050A (es) |
AU (1) | AU2020221837A1 (es) |
BR (1) | BR112021015996A2 (es) |
CA (1) | CA3129829A1 (es) |
CO (1) | CO2021011919A2 (es) |
IL (1) | IL285445A (es) |
MA (1) | MA54948A (es) |
MX (1) | MX2021009743A (es) |
SG (1) | SG11202108744WA (es) |
WO (1) | WO2020167976A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2905100T3 (es) | 2017-08-15 | 2022-04-07 | Agios Pharmaceuticals Inc | Activadores de piruvato quinasa para su uso en el tratamiento de trastornos sanguíneos |
AU2021311597A1 (en) * | 2020-07-21 | 2023-02-02 | The Regents Of The University Of Michigan | Compositions and methods for activating pyruvate kinase |
TW202245758A (zh) | 2021-02-08 | 2022-12-01 | 美商全球血液治療公司 | 作為丙酮酸激酶活化劑之吡咯啶-吡唑 |
CA3231728A1 (en) | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
TW202325288A (zh) | 2021-11-05 | 2023-07-01 | 英商喜翠克斯治療有限公司 | 新穎化合物 |
CA3238806A1 (en) | 2021-12-22 | 2023-06-29 | Sitryx Therapeutics Limited | Phthalazine derivatives as pyruvate kinase modulators |
CN115487190A (zh) * | 2022-11-01 | 2022-12-20 | 复旦大学附属中山医院 | 丙酮酸激酶m2激活剂在制备治疗***性红斑狼疮的药物中的应用 |
WO2024095012A1 (en) | 2022-11-04 | 2024-05-10 | Sitryx Therapeutics Limited | Phthalazine derivatives as pyruvate kinase modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2344453B1 (en) * | 2008-10-09 | 2016-12-28 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
WO2011002817A1 (en) | 2009-06-29 | 2011-01-06 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
ES2675903T3 (es) | 2011-05-03 | 2018-07-13 | Agios Pharmaceuticals, Inc. | Activadores de piruvato quinasa para uso en terapia |
CA2834692A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
US9403792B2 (en) * | 2011-05-03 | 2016-08-02 | Agios Pharmaceuticals, Inc | Methods of using pyruvate kinase activators |
WO2014018851A1 (en) | 2012-07-26 | 2014-01-30 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
ES2905100T3 (es) * | 2017-08-15 | 2022-04-07 | Agios Pharmaceuticals Inc | Activadores de piruvato quinasa para su uso en el tratamiento de trastornos sanguíneos |
-
2020
- 2020-02-12 CA CA3129829A patent/CA3129829A1/en active Pending
- 2020-02-12 KR KR1020217029380A patent/KR20210128435A/ko not_active Application Discontinuation
- 2020-02-12 BR BR112021015996A patent/BR112021015996A2/pt not_active IP Right Cessation
- 2020-02-12 MX MX2021009743A patent/MX2021009743A/es unknown
- 2020-02-12 AU AU2020221837A patent/AU2020221837A1/en not_active Abandoned
- 2020-02-12 CN CN202080027241.9A patent/CN113646050A/zh active Pending
- 2020-02-12 WO PCT/US2020/017965 patent/WO2020167976A1/en unknown
- 2020-02-12 MA MA054948A patent/MA54948A/fr unknown
- 2020-02-12 US US17/429,073 patent/US20220127267A1/en active Pending
- 2020-02-12 EP EP20713430.5A patent/EP3924056A1/en not_active Withdrawn
- 2020-02-12 SG SG11202108744WA patent/SG11202108744WA/en unknown
- 2020-02-12 JP JP2021547190A patent/JP2022520090A/ja not_active Withdrawn
-
2021
- 2021-08-08 IL IL285445A patent/IL285445A/en unknown
- 2021-09-10 CO CONC2021/0011919A patent/CO2021011919A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202108744WA (en) | 2021-09-29 |
US20220127267A1 (en) | 2022-04-28 |
WO2020167976A1 (en) | 2020-08-20 |
MA54948A (fr) | 2021-12-22 |
CO2021011919A2 (es) | 2021-12-10 |
CA3129829A1 (en) | 2020-08-20 |
IL285445A (en) | 2021-09-30 |
EP3924056A1 (en) | 2021-12-22 |
CN113646050A (zh) | 2021-11-12 |
KR20210128435A (ko) | 2021-10-26 |
JP2022520090A (ja) | 2022-03-28 |
AU2020221837A1 (en) | 2021-09-02 |
BR112021015996A2 (pt) | 2021-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021009743A (es) | Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes. | |
CR20200588A (es) | Compuestos novedosos | |
MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
CR20200532A (es) | Compuestos de heteroarilo tetracíclicos | |
MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
MX2021010674A (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos. | |
ZA202201329B (en) | Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders | |
CR20220312A (es) | Compuestos tricíclicos sustituidos | |
MXPA06009475A (es) | Derivados de quinazolina y usos terapeuticos de los mismos. | |
EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
CA3082011A1 (en) | Methods of using substituted pyrazole and pyrrole compounds and for treatment of hyperproliferative diseases | |
TW200621762A (en) | Novel compounds | |
CR20200123A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
TW200633698A (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
MX2023004920A (es) | Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6). | |
MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
PH12020550168A1 (en) | Griseofulvin compound and pharmaceutical use thereof | |
WO2021011713A8 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
MX2021007247A (es) | Derivados de rapamicina. | |
MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
JOP20210275A1 (ar) | مشتقات 3-أمينو-4h-بنزو[e][4,2,1]ثيادايازين 1,1-داي أكسيد كمثبطات لـ mrgx2 | |
CR20210014A (es) | Derivados de pirrolo [1,2-b] piridazina | |
MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
TW200635592A (en) | Pyridyl-substituted spiro-hydantoin compounds and use thereof | |
JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 |